Search Within

Anthony R Mato

Formats
  1. Meeting Abstract (135)
  2. Journal Article (63)
  3. Review (16)
  4. Research Letter (10)
  5. Editorial (7)
  6. Guidelines (3)
  7. Book Section (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (236)
  2. Center for Hematologic Malignancies (236)
  3. Department of Medicine (236)
  4. Hematologic Malignancies, Division of (236)
  5. Hematology-Oncology Fellows (101)
  6. Lymphoma (47)

More Groups

People
  1. Lindsey Roeker (94)
  2. Andrew Zelenetz (33)
  3. Meghan Thompson (30)
  4. Omar Abdel-Wahab (19)
  5. Maria Palomba (18)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (4)
  2. 2024 (2)
  3. 2023 (22)
  4. 2022 (49)
  5. 2021 (39)
  6. 2020 (52)

More Years

Publications
  1. Blood (82)
  2. Journal of Clinical Oncology (18)
  3. Clinical Lymphoma, Myeloma and Leukemia (16)
  4. Leukemia and Lymphoma (16)
  5. British Journal of Haematology (15)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (94)
  2. American Society of Clinical Oncology (19)
  3. Elsevier Inc. (18)
  4. Taylor & Francis Group (18)
  5. John Wiley & Sons (16)
  6. American Association for Cancer Research (10)

More Publishers

Results (236)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Veneto-STOP study: Sequential assessment of minimal residual disease by next generation sequencing to optimize outcomes and minimize exposure in venetoclax-treated CLL patients
    Meeting Abstract

    Ujjani, C. S.; Roeker, L. E.; Shadman, M.; Whitaker, K. J.; Jacob, A. P.; Geyer, M. B.; Dorsey, C.; Zelenetz, A. D.; Mato, A. R.
    Blood (2019)

    Fulltext@MSK | Save
  • Treatment discontinuation patterns for patients with CLL in the real-world settings: Results from a multi-center study
    Meeting Abstract

    Shadman, M.; Sail, K.; Manzoor, B. S.; Yazdy, M. S.; Hill, B. T.; Tuncer, H. H.; Allan, J. N.; Ujjani, C. S.; Emechebe, N.; Kamalakar, R.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Allogeneic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) in the era of novel agents
    Meeting Abstract

    Roeker, L. E.; Brown, J. R.; Dreger, P.; Lahoud, O. B.; Eyre, T. A.; Brander, D. M.; Skarbnik, A.; Coombs, C. C.; Kim, H. T.; Manchini, S. T.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Treatment sequences and outcomes of patients with CLL treated with venetoclax and other novel agents post introduction of novel therapies
    Meeting Abstract

    Mato, A. R.; Sail, K.; Yazdy, M. S.; Hill, B. T.; Shadman, M.; Manzoor, B. S.; Tuncer, H. H.; Allan, J. N.; Ujjani, C. S.; Sharmokh, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia patients at first relapse: A multi-center outcomes analysis
    Meeting Abstract

    Hu, R.; Wei, W.; Gonter-Aubin, K.; Pinilla Ibarz, J.; Kabel, C. C.; Mato, A. R.; Madanat, Y. F.; Khajavian, S.; Shadman, M.; Hanlon, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Time to second treatment as a proxy for overall survival in CLL/SLL: Identifying risk factors to help guide treatment selection
    Meeting Abstract

    Bantilan, K. S.; Soumerai, J. D.; Roeker, L. E.; Mato, A. R.; Zelenetz, A. D.
    Blood (2019)

    Fulltext@MSK | Save
  • Ongoing results of a phase 1B/2 dose-escalation and cohort-expansion study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor, vecabrutinib, in B-cell malignancies
    Meeting Abstract

    Allan, J. N.; Patel, K.; Mato, A. R.; Wierda, W. G.; Pinilla Ibarz, J.; Choi, M. Y.; O'Brien, S. M.; Sharman, J. P.; Shadman, M.; Gladstone, D. E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Results from a first-in-human, proof-of-concept phase 1 trial in pretreated B-cell malignancies for loxo-305, a next-generation, highly selective, non-covalent BTK inhibitor
    Meeting Abstract

    Mato, A. R.; Flinn, I. W.; Pagel, J. M.; Brown, J. R.; Cheah, C. Y.; Coombs, C. C.; Patel, M. R.; Rothenberg, S. M.; Tsai, D. E.; Ku, N. C.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase Ia/Ib study exploring the synthetic lethality of the orally administered novel BTK inhibitor, Dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide in patients with relapsed/refractory CLL, DLBCL or other B-cell lymphomas
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Foss, F. M.; Isufi, I.; Ding, W.; Brander, D. M.; Sitlinger, A.; Tun, H. W.; Moustafa, M. A.; Kennard, K.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Efficacy of therapies following venetoclax discontinuation in CLL: Focus on B-cell receptor signal transduction inhibitors and cellular therapies
    Meeting Abstract

    Mato, A. R.; Roeker, L. E.; Eyre, T. A.; Jacobs, R.; Hill, B. T.; Lamanna, N.; Brander, D. M.; Shadman, M.; Ujjani, C.; Yazdy, M.; more...
    Blood (2019)

    Fulltext@MSK | Save